A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2002
11/26/2002	US6486201 Agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine
11/26/2002	US6486198 Compounds and methods for the treatment of post traumatic stress disorder
11/26/2002	US6486190 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
11/26/2002	US6486186 Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
11/26/2002	US6486177 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
11/26/2002	US6486172 Quinuclidine-substituted aryl compounds for treatment of disease
11/26/2002	US6486171 Useful in the treatment of some central nervous system disorders including as an antidepressant; 4-(1-(2-naphthyl)ethyl)-4- piperidinyl)thieno(3,2-c)pyridine, for example
11/26/2002	US6486151 N-oxides of heterocyclic esters, amides, thioesters, and ketones
11/26/2002	US6486143 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds
11/26/2002	US6486142 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
11/26/2002	US6486141 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485919 Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof
11/26/2002	US6485911 Methods for determining risk of developing alzheimer's disease by detecting mutations in the presenilin 2 (PS-2) gene
11/26/2002	US6485755 Methods of using electron active compounds for managing cancer
11/26/2002	US6485745 Dosage form exhibits accelerated release of the active agent
11/26/2002	US6485704 Azo compound for type I pototherapy
11/26/2002	CA2258285C Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
11/26/2002	CA2246482C Novel trans-3,4,4a,5,6,10b-hexahydro-2h-naphth¢1,2-b!-1,4-oxazines disubstitutes, process for preparing them and pharmaceutical compounds containing them
11/26/2002	CA2240717C Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
11/26/2002	CA2231364C Novel n-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
11/26/2002	CA2228635C Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
11/26/2002	CA2111573C Cadherin materials and methods
11/26/2002	CA2066913C Novel binding peptides
11/23/2002	CA2386740A1 Combination treatment for alcoholism and alcohol dependence
11/23/2002	CA2386287A1 Combination treatment for depression and anxiety
11/21/2002	WO2002093177A2 Assays for identifying modulators of rhomboid polypeptides
11/21/2002	WO2002093164A2 Pyridylpyrimidine derivatives as effective compounds against prion diseases
11/21/2002	WO2002092817A1 Functions for d52 and ra006 nucleic acids and polypeptides
11/21/2002	WO2002092788A2 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	WO2002092773A2 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/21/2002	WO2002092759A2 Molecules for disease detection and treatment
11/21/2002	WO2002092604A1 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
11/21/2002	WO2002092602A2 PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE
11/21/2002	WO2002092598A1 DIHYDROIMIDAZO [5,1-A]-$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE
11/21/2002	WO2002092597A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092596A1 Novel sulfonate substituted pyrazol pyridine dervivatives
11/21/2002	WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002	WO2002092590A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	WO2002092576A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002	WO2002092571A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	WO2002092568A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002	WO2002092567A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002	WO2002092558A1 Polythiourea lipid derivatives
11/21/2002	WO2002092556A1 Sulfonamide derivatives
11/21/2002	WO2002092553A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	WO2002092540A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
11/21/2002	WO2002092122A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	WO2002092121A1 Novel remedies for neurodegenerative disease
11/21/2002	WO2002092115A2 Method of preventing cell death using segments of neural thread proteins
11/21/2002	WO2002092113A1 Alcoholic valerian extract for improving sleep quality and efficiency, and methods of preparing it
11/21/2002	WO2002092107A1 Method and compositions for treating mammalian nerve tissue injuries
11/21/2002	WO2002092104A1 A pharmaceutical composition comprising lysophosphatidic acid
11/21/2002	WO2002092090A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092088A2 Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts
11/21/2002	WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	WO2002092086A1 Imidazo (1,2-a)-pyridine derivatives as mglur5 antagonists
11/21/2002	WO2002092079A1 Utilization of selective indirubin derivatives as vegf-r inhibitors
11/21/2002	WO2002092075A2 Therapeutic delivery of carbon monoxide
11/21/2002	WO2002092074A1 Remedial agent for myelopathic disease
11/21/2002	WO2002092072A2 Drugs for the treatment of the alzheimer disease
11/21/2002	WO2002092071A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	WO2002092065A2 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092060A1 Abuse-resistant controlled-release opioid dosage form
11/21/2002	WO2002092059A1 Abuse-resistant opioid dosage form
11/21/2002	WO2002092056A1 Compaction process for manufacture of sodium phenytoin dosage form
11/21/2002	WO2002092014A2 Destruction of prions using vibriolysin or variants thereof
11/21/2002	WO2002092013A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002	WO2002091993A2 Estrogen receptor modulators
11/21/2002	WO2002091990A2 Prevention of addiction in pain management
11/21/2002	WO2002091859A1 Agent for sustaining concentration and attentiveness, and food and drink containing the agent
11/21/2002	WO2002091858A1 Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
11/21/2002	WO2002091820A1 Nonhuman model animal of oligodendrocyte development disability
11/21/2002	WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002	WO2002078615A3 Antioxidant nitroxides and nitrones as therapeutic agents
11/21/2002	WO2002077211A8 A virus (cryptovirus) within the rubulavirus genus and uses therefor
11/21/2002	WO2002076381A3 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
11/21/2002	WO2002074784A3 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
11/21/2002	WO2002070513A9 Methods for the preparation of mirtazapine intermediates
11/21/2002	WO2002069976A8 Use of ovarian hormone for increasing neural stem cell number
11/21/2002	WO2002068398A9 New crystal forms of lamotrigine and processes for their preparations
11/21/2002	WO2002066426A3 Fluoro oxindole derivatives as modulators of kcnq potassium channels
11/21/2002	WO2002066068A3 Method of treating neurological diseases
11/21/2002	WO2002062343A3 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/21/2002	WO2002060340A9 Method for identifying maxi-k channel blockers
11/21/2002	WO2002059604A8 Diagnosis and treatment of multiple sclerosis
11/21/2002	WO2002055720A3 Materials and methods relating to protein aggregation in neurodegenerative disease
11/21/2002	WO2002055514A3 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
11/21/2002	WO2002049629A8 Methods for reducing chronic stress in mammals
11/21/2002	WO2002018341A9 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
11/21/2002	WO2002014467A3 Cng2b: a putative human cyclic nucleotide-gated ion channel
11/21/2002	WO2002005799A3 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
11/21/2002	WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002	US20020174446 Identification of genes involved in alzheimer's disease using drosophila melanogaster

1 ... 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 ... 1833